Floatz logo

Eloxatin

Insulinoma

Vanderbilt-Ingram Cancer CenterPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Insulinoma cohort.

Asset / SponsorPhaseRating
Capecitabine
Vanderbilt-Ingram Cancer Center
Phase 2BB
(+)-VINCRISTINE
Shaheen Shagufta
Phase 2B
Irinotecan
Shaheen Shagufta
Phase 2B
Everolimus
Emory University
Phase 2B
Regorafenib
University of Southern California
Phase 2B

View all 20 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →